Login to Your Account

Amgen sues to block competing PCSK9 drug from Sanofi/Regeneron

By Michael Fitzhugh
Staff Writer

Friday, October 17, 2014

Amgen Inc. is throwing a wrench in the gears advancing Sanofi SA's and Regeneron Pharmaceuticals Inc.'s high cholesterol drug alirocumab, seeking an injunction to block the (PCSK9) inhibitor's manufacture and sale over alleged infringement on patents.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription